deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02009579

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

BGOG-cx1/ENGOT-cx1: Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma.

Sponsor: Belgian Gynaecological Oncology Group

Conditions Uterine Cervical Neoplasms
Interventions Nintedanib Placebo
Updated 14 times since 2017 Last updated: Aug 6, 2024 Started: Mar 31, 2014 Primary completion: Jan 31, 2021 Completion: Oct 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02009579, this PHASE2 trial focuses on Uterine Cervical Neoplasms and remains completed. Sponsored by Belgian Gynaecological Oncology Group, it has been updated 14 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Aug 2020 · 7 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Aug 2023 · 16 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jun 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  7. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  8. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  9. Jan 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Belgian Gynaecological Oncology Group
  • Grupo Español de Investigación en Cáncer de Ovario
  • Mario Negri Gynecologic Oncology group (MaNGO)
  • Multicenter Italian Trials in Ovarian Cancer (MITO)
  • North Eastern German Society of Gynaecological Oncology
Data source: Belgian Gynaecological Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aviano, Italy , Berlin, Germany , Brescia, Italy , Brussels, Belgium , Catania, Italy , Charleroi, Belgium , Córdoba, Spain , Dresden, Germany , Edegem, Belgium , Essen, Germany and 18 more locations